Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 636431
                    [Title] => Hearty news from MSD
                    [Summary] => 
A new investigational study of Ezetimibe/Simvastatin, the cholesterol-lowering medicine from MSD (known as Merck in US and Canada) showed that at dosage of 10/20 mg, it reduced the incidence of first major vascular events  defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure  by a highly statistically significant 16.1 percent compared to placebo (p=0.0010).
                    [DatePublished] => 2010-12-07 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

        )

)

OXFORD UNIVERSITY CLINICAL TRIAL SERVICE UNIT

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 636431
                    [Title] => Hearty news from MSD
                    [Summary] => 
A new investigational study of Ezetimibe/Simvastatin, the cholesterol-lowering medicine from MSD (known as Merck in US and Canada) showed that at dosage of 10/20 mg, it reduced the incidence of first major vascular events  defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure  by a highly statistically significant 16.1 percent compared to placebo (p=0.0010).
                    [DatePublished] => 2010-12-07 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

        )

)

abtest

Hearty news from MSD

December 7, 2010 - 12:00am

A new investigational study of Ezetimibe/Simvastatin, the cholesterol-lowering medicine from MSD (known as Merck in US and Canada) showed that at dosage of 10/20 mg, it reduced the incidence of first major vascular...

Health And Family